1.
Trends Biotechnol
; 41(10): 1216-1219, 2023 10.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37236813
RESUMO
Chimeric antigen receptor T cells (CAR-T) have demonstrated their potential to revolutionize cancer treatment. However, manufacturing remains a challenge. Multiple manufacturing innovations [e.g., vector and gene engineering, process improvements, hardware innovation, digital innovation, and point-of-care (POC) manufacturing] have the potential to help realize the full potential of CAR-T therapies.